Kaleido Biosciences, a clinical-stage biotech company with a small molecule approach to treat inflammatory conditions and diseases, announced its decision to halt work on a phase 2 COPD study and terminate its agreement with the COPD Foundation. The company said that these decisions were made in order to realign the resources and refocus their resources on other domains. Kaleido CEO Dan Menichella said that the company had also undertaken layoffs for about 30 percent of the employees, but that it will move ahead with a different mid stage study in ulcerative colitis with a drug candidate named KB295.